home / stock / cfrx / cfrx news

CFRX News and Press, ContraFect Corporation From 07/11/22

Stock Information
Company Name: ContraFect Corporation
Stock Symbol: CFRX
Market: NASDAQ
Website: contrafect.com
Menu
CFRX CFRX Quote CFRX Short CFRX News CFRX Articles CFRX Message Board
Get CFRX Alerts

News, Short Squeeze, Breakout and More Instantly...
CFRX - KE Holdings, Twitter, XPeng among premarket losers' pack

ContraFect ( CFRX ) -19% . United Maritime ( USEA ) -14% . Organovo Holdings ( ONVO ) -9% . Revelation Biosciences ( REVB ) -9% . Melco Resorts & Entertainment ( MLCO ) -7% after Chinese regulators close Macau casinos to cu...
CFRX - Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect's Direct Lytic Agents (DLAs) to Address MRSA Infections

YONKERS, N.Y., June 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the tr...

CFRX - Day One Biopharmaceuticals leads healthcare gainers; ContraFect, SciSparc among losers

Gainers: Day One Biopharmaceuticals (DAWN) +111%. Ekso Bionics Holdings (EKSO) +22%. OptiNose (OPTN) +19%. Tivic Health Systems (TIVC) +10%. Belite Bio (BLTE) +7%. Losers: ContraFect (CFRX) -23%. Reviva Pharmaceuticals Holdings (RVPH) -20%. Neptune Wellness Solutions (NEPT) -19%. Sc...

CFRX - Penny Stocks To Buy Today? 3 To Watch With Analyst Targets Up To 675%

One of the best parts about penny stocks is that there are so many of them right now. Similar to what we saw during the pandemic, hundreds of companies had fallen victim to the broad sector sell-offs this year. It hasn’t only been “start-ups” either. Plenty of househo...
CFRX - Biopharmaceutical Stocks: The Bottoming Process Is Playing Out

Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the decline was the "Class of 2021 IPOs", which featured many companies with preclinical compou...

CFRX - ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022

YONKERS, N.Y., June 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the tr...

CFRX - Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman

Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Ve...
CFRX - ContraFect Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

YONKERS, N.Y., May 20, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) (ContraFect) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal...

CFRX - Contrafect GAAP EPS of -$0.51

Contrafect press release (NASDAQ:CFRX): Q1 GAAP EPS of -$0.51. Cash and cash equivalents of $9.6M For further details see: Contrafect GAAP EPS of -$0.51

CFRX - ContraFect Reports First Quarter 2022 Financial Results and Provides Business Update

YONKERS, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the...
Previous 10 Next 10